Route of drug administration in out-of-hospital cardiac arrest: A protocol for a randomised controlled trial (PARAMEDIC-3)

Keith Couper, Chen Ji, Ranjit Lall, Charles D Deakin, Rachael Fothergill, John Long, James Mason, Felix Michelet, Jerry P Nolan, Henry Nwankwo, Tom Quinn, Anne-Marie Slowther, Michael A Smyth, Alison Walker, Loraine Chowdhury, Chloe Norman, Laurille Sprauve, Kath Starr, Sara Wood, Steve BellGemma Bradley, Martina Brown, Shona Brown, Karl Charlton, Alison Coppola, Charlotte Evans, Christine Evans, Theresa Foster, Michelle Jackson, Justin Kearney, Nigel Lang, Adam Mellett-Smith, Ria Osborne, Helen Pocock, Nigel Rees, Robert Spaight, Belinda Tibbetts, Gregory A Whitley, Jason Wiles, Julia Williams, Adam Wright, Gavin D Perkins

Research output: Contribution to journalArticlepeer-review

1 Downloads (Pure)

Abstract

AIMS: The PARAMEDIC-3 trial evaluates the clinical and cost-effectiveness of an intraosseous first strategy, compared with an intravenous first strategy, for drug administration in adults who have sustained an out-of-hospital cardiac arrest.

METHODS: PARAMEDIC-3 is a pragmatic, allocation concealed, open-label, multi-centre, superiority randomised controlled trial. It will recruit 15,000 patients across English and Welsh ambulance services. Adults who have sustained an out-of-hospital cardiac arrest are individually randomised to an intraosseous access first strategy or intravenous access first strategy in a 1:1 ratio through an opaque, sealed envelope system. The randomised allocation determines the route used for the first two attempts at vascular access. Participants are initially enrolled under a deferred consent model.The primary clinical-effectiveness outcome is survival at 30-days. Secondary outcomes include return of spontaneous circulation, neurological functional outcome, and health-related quality of life. Participants are followed-up to six-months following cardiac arrest. The primary health economic outcome is incremental cost per quality-adjusted life year gained.

CONCLUSION: The PARAMEDIC-3 trial will provide key information on the clinical and cost-effectiveness of drug route in out-of-hospital cardiac arrest.Trial registration: ISRCTN14223494, registered 16/08/2021, prospectively registered.

Original languageEnglish
Article number100544
Number of pages7
JournalResuscitation Plus
Volume17
Early online date30 Dec 2023
DOIs
Publication statusPublished - 30 Mar 2024

Fingerprint

Dive into the research topics of 'Route of drug administration in out-of-hospital cardiac arrest: A protocol for a randomised controlled trial (PARAMEDIC-3)'. Together they form a unique fingerprint.

Cite this